<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636347</url>
  </required_header>
  <id_info>
    <org_study_id>MPH966-2-01</org_study_id>
    <secondary_id>2018-001309-95</secondary_id>
    <nct_id>NCT03636347</nct_id>
  </id_info>
  <brief_title>A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.</brief_title>
  <acronym>ASTRAEUS</acronym>
  <official_title>A Phase 2, Proof-of-concept, Multicentre, Double-blind, Randomised, Dose-ascending, Sequential Group, Placebo-controlled Study to Evaluate the Mechanistic Effect, Safety, and Tolerability of 12 Weeks Twice Daily Oral Administration of Alvelestat (MPH966) in Participants With Alpha-1 Antitrypsin Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil
      elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare
      variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of
      different blood and sputum biomarkers related to lung damage, inflammation and elastase
      activity will be measured over a 12 week period. The effect on lung function and respiratory
      symptoms will also be measured.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">July 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, dose ascending, sequential group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on blood biomarkers of neutrophil elastase activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Within-individual % change from baseline in plasma desmosine/isodesmosine at end of treatment compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on other blood biomarkers of neutrophil elastase activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall change from baseline in plasma desmosine/isodesmosine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in St. George's Respiratory Questionnaire (SGRQ-C) at end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total score</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pulmonary function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in forced expiratory volume in 1 second (FEV1)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <condition>Emphysema</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alvelestat oral tablet - dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPH966</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alvelestat oral tablet - dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPH966</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>twice daily administration</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvelestat oral tablet - dose 1</intervention_name>
    <description>twice daily administration</description>
    <arm_group_label>Alvelestat oral tablet - dose 1</arm_group_label>
    <other_name>MPH966</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvelestat oral tablet - dose 2</intervention_name>
    <description>twice daily administration</description>
    <arm_group_label>Alvelestat oral tablet - dose 2</arm_group_label>
    <other_name>MPH966</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of alpha-1-anti-trypsin deficiency and a PiZZ or
             null geno/phenotype and serum anti-alpha1 antitrypsin levels of less than 11uM

          -  FEV1 â‰¥25% predicted

          -  Computerised tomography (CT) scan evidence of emphysema

          -  Non-smokers

        Exclusion Criteria:

          -  Primary diagnosis of bronchiectasis

          -  An ongoing acute exacerbation of the underlying lung disease

          -  Underlying liver disease or abnormal liver function tests

          -  Previous augmentation therapy within 6 months of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Stockley, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian Hodgson, PhD</last_name>
    <phone>+44 (0)333 0237 300</phone>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jackie Parkin, MD</last_name>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Centre</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University Lung Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Heart Lung Innovation, St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inspiration Research Ltd</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>Enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>Enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synddansk Universitet (SDU) - Odense University</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Gruzilicy Chorob Pluc</name>
      <address>
        <city>Warsaw</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sierrallana</name>
      <address>
        <city>Torrelavega</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC Gothia Forum Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals Foundation NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Trust</name>
      <address>
        <city>Exeter</city>
        <zip>PhD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 7RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SWP 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astraeus-alpha1.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PiZZ or Null</keyword>
  <keyword>Neutrophil elastase inhibitor</keyword>
  <keyword>Alpha-1</keyword>
  <keyword>Alvelestat</keyword>
  <keyword>AZD9668</keyword>
  <keyword>MPH966</keyword>
  <keyword>Rare variant genotype</keyword>
  <keyword>Astraeus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

